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Abstract: The coronavirus SARS-CoV-2 is the cause of the ongoing COVID-19 pandemic. Most
SARS-CoV-2 infections are mild or even asymptomatic. However, a small fraction of infected
individuals develops severe, life-threatening disease, which is caused by an uncontrolled immune
response resulting in hyperinflammation. However, the factors predisposing individuals to severe
disease remain poorly understood. Here, we show that levels of CD47, which is known to mediate
immune escape in cancer and virus-infected cells, are elevated in SARS-CoV-2-infected Caco-2 cells,
Calu-3 cells, and air−liquid interface cultures of primary human bronchial epithelial cells. Moreover,
SARS-CoV-2 infection increases SIRPalpha levels, the binding partner of CD47, on primary human
monocytes. Systematic literature searches further indicated that known risk factors such as older
age and diabetes are associated with increased CD47 levels. High CD47 levels contribute to vascular
disease, vasoconstriction, and hypertension, conditions that may predispose SARS-CoV-2-infected
individuals to COVID-19-related complications such as pulmonary hypertension, lung fibrosis,
myocardial injury, stroke, and acute kidney injury. Hence, age-related and virus-induced CD47
expression is a candidate mechanism potentially contributing to severe COVID-19, as well as a
therapeutic target, which may be addressed by antibodies and small molecules. Further research will
be needed to investigate the potential involvement of CD47 and SIRPalpha in COVID-19 pathology.
Our data should encourage other research groups to consider the potential relevance of the CD47/
SIRPalpha axis in their COVID-19 research.
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1. Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is causing the ongoing
coronavirus disease 2019 (COVID-19) outbreak [1,2], which has resulted in more than
210 million confirmed cases and more than 4.4 million confirmed COVID-19-associated
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deaths so far [3]. Older age; being male; and conditions such as diabetes, hypertension,
and obesity are associated with an increased risk of severe COVID-19 [1,4].
The first COVID-19 vaccines have been developed [2], and their roll-out has started
in many countries. However, it will take a significant time until large parts of the global
population will be vaccinated, and there is growing concern about the emergence of escape
variants that can bypass the immunity conferred by the current vaccines and previous
SARS-CoV-2 infections [5–10]. Thus, for the foreseeable future, there will be a need for
improved COVID-19 therapies.
Currently, the therapeutic options for COVID-19 are still very limited [2,11]. COVID-19
therapies can either directly inhibit SARS-CoV-2 replication or target other COVID-19-associated
pathophysiological processes, such as corticosteroids, which are anticipated to control
COVID-19-related cytokine storm and hyperinflammation [12]. Dexamethasone and poten-
tially other corticosteroids increase survival in patients who depend on oxygen support [13,14].
In a controlled open-label trial, dexamethasone reduced mortality in patients receiving
oxygen with (from 41.1% to 29.3%) or without (from 26.2% to 23.3%) mechanical venti-
lation, but increased mortality in patients not requiring oxygen support [13]. Other im-
munomodulatory therapy candidates are being tested, but conclusive results are pending [11].
Further COVID-19 therapeutics under investigations include anticoagulants that target
COVID-19-induced systemic coagulation and thrombosis (coagulopathy) [15].
However, it would be much better to have effective antiviral treatments that reliably
prevent COVID-19 disease progression to a stage where immunomodulators and antico-
agulants are needed. The antiviral drug remdesivir was initially described to reduce the
recovery time from 15 to 10 days, and the 29-day mortality from 15.2% to 11.4% [11,16].
However, other trials did not confirm this and conclusive evidence on the efficacy of
remdesivir remains to be established [11]. The JAK inhibitor baricitinib, which interferes
with cytokine signaling, was reported to improve therapy outcomes in combination with
remdesivir in a double-blind, randomized, placebo-controlled trial, in which patients were
either treated with remdesivir plus baricitinib or remdesivir plus placebo [17]. Moreover,
convalescent sera and monoclonal antibodies are under clinical investigation for COVID-19
treatment [18–20].
Ideally, antiviral therapies are used early in the disease course to prevent disease
progression to the later immunopathology-driven stages [21]. However, only a small
proportion of patients develop severe disease [21]. Therefore, a better understanding of the
underlying processes is required to identify the patients who could develop severe disease
as early as possible.
CD47 is the receptor of thrombospondin-1 (THBS1) and the counter-receptor for
signal regulatory protein-α (SIRPα). CD47 interaction with SIRPα inhibits the activation
of macrophages and dendritic cells, and thrombospondin-1/ CD47 signaling inhibits
T cell activation [22,23]. Cellular surface levels of CD47 modulate immune responses in
infectious diseases caused by parasites, bacteria, and viruses [22]. Typically, high CD47
levels prevent the immune recognition of virus-infected cells [22,24]. Moreover, cancer
cells have been described to avoid immune recognition by upregulating CD47 [22]. Here,
we investigated the potential role of the ubiquitously expressed cell surface glycoprotein
CD47 in severe COVID-19.
2. Materials and Methods
2.1. Cell Culture
Calu-3 cells (ATCC, #HTB-55) were grown at 37 ◦C in minimal essential medium
(MEM) supplemented with 10% fetal bovine serum (FBS), 100 IU/mL penicillin, and
100 µg/mL of streptomycin. All of the culture reagents were purchased from Sigma. The
cells were regularly authenticated by short tandem repeat (STR) analysis and were tested
for mycoplasma contamination.
Primary human bronchial epithelial cells were purchased from ScienceCell. For differ-
entiation to air−liquid interface (ALI) cultures, the cells were thawed and passaged once in
Curr. Issues Mol. Biol. 2021, 43 1214
PneumaCult-Ex Medium (StemCell Technologies, Vancouver, BC, Kanada) and then seeded
on transwell inserts (12-well plate, Sarstedt, Nümbrecht, Germany) at 4 × 104 cells/insert.
Once the cell layers reached confluency, the medium on the apical side of the transwell
was removed, and the medium in the basal chamber was replaced with PneumaCult ALI
Maintenance Medium (StemCell Technologies, Vancouver, BC, Kanada) including an an-
tibiotic/antimycotic solution (Sigma Aldrich, Saint Louis, MO, USA) and MycoZap Plus
PR (Lonza, Basel, Switzerland). Over a period of four weeks, the medium was changed and
cell layers were washed with PBS every other day. Criteria for successful differentiation
were the development of ciliated cells and ciliary movement, an increase in transepithelial
electric resistance indicative of the formation of tight junctions, and mucus production.
Human monocytes were isolated from the buffy coats of healthy donors (RK-Blutspendedienst
Baden-Württemberg-Hessen, Institut für Transfusionsmedizin und Immunhämatologie
Frankfurt am Main, Germany). After centrifugation on a Ficoll (Pancoll, PAN-Biotech,
Aidenbach, Germany) density gradient, mononuclear cells were collected from the interface,
washed with PBS, and plated on cell culture dishes (Cell+, Saarstedt, Nümbrecht, Germany)
in RPMI1640 (Gibco, ThermoFisher Scientific, Waltham, MA, USA) supplemented with
100 IU/mL penicillin and 100 µg/mL streptomycin. After incubation for 90 min (37 ◦C,
5% CO2), non-adherent cells were removed, and the medium was changed to RPMI1640
supplemented with 100 IU/mL penicillin, 100 µg/mL of streptomycin, and 3% human
serum (RK-Blutspendedienst Baden-Württemberg-Hessen, Institut für Transfusionsmedi-
zin und Immunhämatologie Frankfurt am Main, Germany).
2.2. Virus Infection
SARS-CoV-2/7/Human/2020/Frankfurt (SARS-CoV-2/FFM7) was isolated and culti-
vated in Caco2 cells (DSMZ, #AC169), as previously described [25,26]. Virus titers were
determined as TCID50/mL in confluent cells in 96-well microtiter plates [27,28].
Monocytes were infected at an MOI of 1 with SARS-CoV-2/FFM7 for 2 h. After
infection, the cells were washed three times with PBS and subsequently cultivated in
RPMI1640 (Gibco) supplemented with 100 IU/mL penicillin and 100 µg/mL streptomycin.
2.3. Western Blot
The cells were lysed using a Triton-X-100 sample buffer, and the proteins were
separated by SDS-PAGE. Detection occurred using specific antibodies against CD47
(1:100 dilution, CD47 Antibody, anti-human, Biotin, REAfinity™, # 130-101-343, Miltenyi
Biotec, Bergisch Gladbach, Germany), SARS-CoV-2 N (1:1000 dilution, SARS-CoV-2 Nucle-
ocapsid Antibody, Rabbit MAb, #40143-R019, Sino Biological, Beijing, China), SIRPα (1:1000
dilution, SIRPα/SHPS1 (D6I3M) Rabbit mAb #13379, Cell Signaling, Danvers, MA, USA),
and GAPDH (1:1000 dilution, Anti-G3PDH Human Polyclonal Antibody, #2275-PC-100,
Trevigen, Gaithersburg, MD, USA). Protein bands were visualized and quantified by laser-
induced fluorescence using an infrared scanner for protein quantification (Odyssey, Li-Cor
Biosciences, Bad Homburg vor der Höhe, Germany).
2.4. qPCR
SARS-CoV-2 RNA from cell culture supernatant samples was isolated using the AVL
buffer and QIAamp Viral RNA Kit (Qiagen, Vienna, Austria) according to the manufac-
turer’s instructions. SARS-CoV-2 RNA from the cell lysates was isolated using an RTL
Buffer and the RNeasy Mini Kit (Qiagen, Vienna, Austria), according to the manufacturer’s
instructions. Absorbance-based quantification of the RNA yield was performed using
the Genesys 10S UV−ViIS Spectrophotometer (Thermo Scientific, Waltham, MA, USA).
RNA was subjected to OneStep qRT-PCR analysis using the Luna Universal One-Step
RT-qPCR Kit (New England Biolabs, Hitchin, UK) and a CFX96 Real-Time System, C1000
Touch Thermal Cycler. Primers were adapted from the WHO protocol29 targeting the
open reading frame for RNA-dependent RNA polymerase (RdRp): RdRP_SARSr-F2 (GTG
ARA TGG TCA TGT GTG GCG G) and RdRP_SARSr-R1 (CAR ATG TTA AAS ACA CTA
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TTA GCA TA) using 0.4 µM per reaction. Standard curves were created using plasmid
DNA (pEX-A128-RdRP) harboring the corresponding amplicon regions for the RdRP target
sequence according to GenBank accession number NC_045512. For each condition three
biological replicates were used. The mean and standard deviation were calculated for
each group.
2.5. Data Acquisition and Analysis
Normalized protein abundance data from SARS-CoV-2-infected Caco-2 cells were
derived from a recent publication [29] and are available from the PRIDE repository [30]
(dataset identifier PXD017710). Data were subsequently normalized using summed inten-
sity normalization for sample loading, followed by internal reference scaling and trimmed
mean of M normalization. Mean protein abundance was plotted using the function ggdotplot
of the R package ggpubr. p-values were determined by two-sided Student’s t-test.
Raw read counts from SARS-CoV-2-infected Calu-3 cells were derived from a recent
publication [31] via the Gene Expression Omnibus (GEO) database (accession: GSE147507)
and were processed using DESeq2. Normalized gene counts were plotted using the function
ggdotplot of the R package ggpubr. p-values were determined by two-sided Student’s t-test.
2.6. Literature Review
Relevant articles were identified by using the search terms “CD47 aging”, “CD47
hypertension”, “CD47 diabetes”, and “CD47 obesity” in PubMed (https://pubmed.ncbi.
nlm.nih.gov accessed on 17 February 2021) on the basis of the principles outlined in the
PRISMA guidelines (http://prisma-statement.org accessed on 17 February 2021). Articles
in English were included in the analysis when they contained original data on the influence
of aging, diabetes, diabetes, or obesity on CD47 expression levels and/or the relevance of
CD47 with regard to pathological conditions observed in severe COVID-19. Two reviewers
independently analyzed the articles for relevant information and then agreed a list of
relevant articles.
3. Results
3.1. SARS-CoV-2 Infection Results in Enhanced CD47 Expression
A publicly available proteomics dataset [29] indicated an increased CD47 expression
in SARS-CoV-2-infected Caco2 colorectal carcinoma cells (Figure 1A). We also detected
enhanced CD47 levels in SARS-CoV-2-infected primary human bronchial epithelial cells
(HBE) grown in air−liquid interface (ALI) cultures [32] and Calu-3 lung cancer cells
(Figures 1B and S1). An analysis of the transcriptomics data from another study also
indicated increased CD47 levels in SARS-CoV-2-infected Calu-3 cells (Figure S2) [31]. Flow
cytometry analysis confirmed increased CD47 levels in SARS-CoV-2-infected Caco2 cells
(Figure S3).
3.2. Increased SIRPα Levels in SARS-CoV-2-Infected Monocytes
CD47 inhibits the activity of innate immune cells via the interaction with SIRPα [22,23].
Hence, we next investigated whether the SARS-CoV-2 infection of monocytes may impact
SIRPα levels. SARS-CoV-2 did not result in a productive infection of primary human
monocytes as indicated by a lack of an increase in genomic RNA levels (Figure 2A).
However, SARS-CoV-2 infection resulted in increased SIRPα levels in primary monocytes
(Figures 2B, S4 and S5). Hence, SARS-CoV-2 may interfere with both players of the
CD47/SIRPα axis.
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Figure 1. SARS-CoV-2 infection is associated with increased CD47 levels. (A) TF protein abundance in uninfected
(control) and SARS-CoV-2-infected (virus) Caco-2 cells (normalized signal intensity, data derived from [23]). p-values
were determined using two-sided Student’s t-test. (B) CD47 and SARS-CoV-2 N protein levels and virus titers (genomic
RNA determined by PCR) in SARS-CoV-2 strain FFM7 (MOI 1)-infected air−liquid interface cultures of primary human
bronchial epithelial (HBE) cells and SARS-CoV-2 strain FFM7 (MOI 0.1)-infected Calu-3 cells. Uncropped blots are provided
in Figure S1. p-values were determined by two-sided Student’s t-test. * p < 0.05, ** p < 0.01.
Figure 2. SARS-CoV-2 infection increases SIRPα in primary human monocytes. (A) SARS-CoV-2. The (MOI 1) infection of
primary human monocytes does not result in the production of genomic viral RNA, as detected by PCR. (B) SARS-CoV-2
strain FFM7 (MOI 1)-infected primary human monocytes display enhanced SIRPα levels. Uncropped blots are provided in
Figure S4. Quantification of the protein levels is provided in Figure S5.
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3.3. CD47 and COVID-19 Risk Factors
To further investigate the potential role of CD47 in severe COVID-19, we performed
systematic literature searches on the relationship of CD47 and the known COVID-19 risk
factors of “ageing”, “diabetes”, and “obesity”.
3.3.1. CD47 and Aging
The risk of severe COVID-19 disease and COVID-19 death increases with age [1]. A lit-
erature search in PubMed (https://pubmed.ncbi.nlm.nih.gov, accessed on 17 February 2020)
using the terms “CD47” and “aging” resulted in 62 hits (Table S1). Eight of these articles
contained information that supports a link between age-related increased CD47 levels and
an elevated risk of severe COVID-19 (Figure 3 and Table S1). One article suggested that
alpha-tocopherol reduced age-associated streptococcus pneumoniae lung infection in mice
through CD47 downregulation [33], which is in accordance with the known immunosup-
pressive functions of CD47 [22,23].
Figure 3. Results of the PubMed (https://pubmed.ncbi.nlm.nih.gov accessed on 17 February 2021) literature search for
“CD47 aging” (A) and “CD47 hypertension” (B). (C) Overview figure of the data derived from the literature searches.
Age-related increased CD47 levels may contribute to pathogenic conditions associated with severe COVID-19.
The remaining seven articles reported on age-related increased CD47 levels in vas-
cular cells that are associated with reduced vasodilatation and blood flow (Table S1),
as CD47 signaling inhibits NO-mediated activation of soluble guanylate cyclase and in
turn vasodilatation [34,35]. As reduced vasodilatation can cause hypertension [36], we per-
formed a follow-up literature search using the search terms “CD47 hypertension” (Table S2).
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This resulted in 20 hits, including a further six relevant studies (Figure 3B and Table S2).
The evidence supporting a link between aging and/or hypertension and increased CD47
levels is summarized in Table 1.
Table 1. Evidence supporting a link between aging and/or hypertension and increased CD47 levels.
Reference Link between Aging and/or Hypertension and Increased CD47 Levels
[33] CD47 downregulation may be involved in the alpha-tocopherol-mediated inhibition of age-associatedstreptococcus pneumoniae lung infection in mice
[37] Blocking thrombospondin-1/CD47 signaling alleviates deleterious effects of aging on tissueresponses to ischemia
[38] CD47 null mice indicate that CD47 functions as a vasopressor
[39]
CD47-null mice are leaner—loss of signaling from the TSP1-CD47 system promotes the accumulation of
normally functioning mitochondria in a tissue-specific and age-dependent fashion, leading to enhanced
physical performance, lower reactive oxygen species production, and more efficient metabolism
[40] High CD47 levels promote pulmonary arterial hypertension in the lungs from humans and mice
[41] TSP1-CD47 signaling is upregulated in clinical pulmonary hypertension and contributes to pulmonary arterialvasculopathy and dysfunction
[42] Increased THBS1/CD47 signaling contributes to reduced skin blood flow and wound healing in aged mice
[43] CD47 blocks NO-mediated vasodilatation
[44] THBS1/CD47 signaling drives endothelial cell senescence
[45] TSP1 promotes ageing-associated human and mouse endothelial cell senescence through CD47
[46] Increased CD47 expression causes age-associated deterioration in angiogenesis, blood flow,and glucose homeostasis
[47] Increased CD47 levels in the lung of a sickle cell disease patient with pulmonary arterial hypertensionrelative to control tissues
[48] Pulmonary hypertension reduced in a CD47-null mouse model of sickle cell disease
[49] Anti-CD47 antibodies reversed fibrosis in various organs in mouse models
Initial experiments showed that loss or inhibition of CD47 prevented age- and diet-induced
vasculopathy and reduced damage caused by ischemic injury in mice [37]. CD47-deficient mice
indicated that CD47 functions as a vasopressor, and the mice were also shown to be leaner
and to display an enhanced physical performance and a more efficient metabolism [38,39].
In agreement, CD47 was upregulated in clinical pulmonary hypertension and contributed
to pulmonary arterial vasculopathy and dysfunction in mouse models [40,41]. Age-related
increased CD47 levels further affected peripheral blood flow and wound healing in
mice [42] and NO-mediated vasodilatation of coronary arterioles of rats [43]. Moreover,
thrombospondin-1/CD47 signaling was shown to induce ageing-associated senescence in
endothelial cells [44,45] and age-associated deterioration in angiogenesis, blood flow, and
glucose homeostasis [46].
Increased CD47 levels were also detected in the lungs of a sickle cell disease patient
with pulmonary arterial hypertension, and vasculopathy and pulmonary hypertension
were reduced in a CD47-null mouse model of sickle cell disease [47,48]. Finally, anti-CD47
antibodies reversed fibrosis in various organs in mouse models [49], which may be relevant
in the context of COVID-19-associated pulmonary fibrosis [50].
In addition to their immunosuppressive activity, ageing-related increased CD47 levels
may thus be involved in vascular disease, vasoconstriction, and hypertension, and pre-
dispose COVID-19 patients to related pathologies such as pulmonary hypertension, lung
fibrosis, myocardial injury, stroke, and acute kidney injury [4,50–57].
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3.3.2. CD47 and Diabetes
Diabetes has been associated with an increased risk of severe COVID-19 and COVID-
19-related death [4]. A PubMed search for “CD47 diabetes” produced 47 hits, nine of which
reported increased CD47 levels in response to hyperglycemia and/or diabetes (Figure 4A
and Table S3).
Figure 4. Results of the PubMed (https://pubmed.ncbi.nlm.nih.gov accessed on 17 February 2021) literature search for
“CD47 diabetes” (A). (B) Overview figure of the data derived from the literature search. Hyperglycemia- and diabetes-
induced increased CD47 levels may contribute to the immune escape of SARS-CoV-2-infected cells.
Hyperglycemia protected CD47 from cleavage, resulting in increased CD47 levels [58–61].
In agreement, increased CD47 levels were detected in various cell types and tissues in
rat diabetes models and diabetes patients [62–66] (Table 2). Therefore, diabetes-induced
increased CD47 levels may interfere with the recognition of SARS-CoV-2-infected cells by
the immune system [22,23] (Figure 4B).
Table 2. Evidence supporting a link between diabetes and increased CD47 levels.
Reference Link between Aging and/ or Hypertension and Increased CD47 Levels
[58] Hyperglycemia protects CD47 from cleavage
[59] Hyperglycemia protects CD47 from cleavage
[60] Hyperglycemia protects CD47 from cleavage
[61] Hyperglycemia protects CD47 from cleavage
[62] CD47 is involved in pathophysiological changes in retinal cells in response to hyperglycemia in cell cultures and rats
[63] Elevated CD47 mRNA levels both in the hippocampus and prefrontal cortex of a type-2 diabetes rat model
[64] Increased levels of CD47 in epiretinal membranes with active neovascularization in proliferative diabetic retinopathy
[65] Increased THBS1/CD47 signaling in bone marrow-derived angiogenic cells in a rat diabetes model
[66] Increased diabetes-associated CD47 levels inhibit angiogenesis and wound healing in a diabetes model in rats
3.3.3. CD47 and Obesity
As obesity is another risk factor for severe COVID-19 [4], we also performed a PubMed
search for “CD47 obesity”, which resulted in eight hits, two of which provided potentially
relevant information (Table S4). The results indicated that CD47-deficient mice were leaner,
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probably as a consequence of elevated lipolysis [67,68]. Hence, low CD47 levels may be
associated both with lower weight and increased immune recognition of virus-infected
cells [22,23,67,68], but there is no direct evidence suggesting that obesity may also directly
increase CD47 expression. However, obesity may at least indirectly contribute to enhanced
CD47 levels as a risk factor for diabetes and hypertension [4].
4. Discussion
Here, we show that the levels of CD47 are elevated in SARS-CoV-2-infected Caco-2
cells, Calu-3 cells, and air−liquid interface cultures of primary human bronchial epithe-
lial cells. CD47 exerts an immunosuppressive activity via interaction with SIRPα in im-
mune cells and as a thrombospondin-1 receptor [22,23]. In this context, human CD47
expression is discussed as a strategy to enable the xenotransplantation of organs from
pigs to humans [69,70]. Moreover, a high CD47 expression is an immune escape mecha-
nism observed in cancer cells, and anti-CD47 antibodies are under investigation as can-
cer immunotherapeutics [23,71]. Due its immunosuppressive action, CD47 expression is
also discussed as a target for the treatment of viral and bacterial pathogens, including
SARS-CoV-2 [22,24,72]. It has been demonstrated that cells infected with different viruses
display enhanced CD47 levels, which function as a “do not eat me” signal, which inter-
feres with the immune recognition of virus-infected cells [24]. Thus, our data indicating
increased CD47 levels in a range of SARS-CoV-2 infection models and clinical samples
further support the potential role of CD47 as a drug target for the mediation of a more
effective antiviral immune response.
Moreover, we found that, although SARS-CoV-2 did not replicate in primary human
monocytes, it increased the levels of the CD47 binding partner SIRPα in these cells. Hence,
SARS-CoV-2 infection may affect the immune recognition of SARS-CoV-2-infected cells by
upregulating both players of the CD47/SIRPα axis. Notably, other viruses and bacteria
have previously been described to increase host cell SIRPα levels [73,74]. Moreover, ele-
vated SIRP-α expression was recently reported in blood mononuclear cells of COVID-19
patients [75], and the CD47/SIRP-α interaction was associated with lung damage in severe
COVID-19 [76].
High SARS-CoV-2 loads are associated with more severe COVID-19 and a higher risk
of patient death [77,78]. Therefore, high CD47 and/or SIRPα levels may affect initial virus
control resulting in enhanced virus levels, which may eventually lead to the hyperinflam-
mation and immunopathology observed in severe COVID-19. Moreover, innate immune
responses appear to be critically involved in the early control of SARS-CoV-2, and the
deregulation of monocytes and macrophages seems to be a factor contributing to severe
COVID-19 [79,80].
Older age, diabetes, and obesity are known risk factors for COVID-19 morbidity
and mortality [1,4]. Hence, we performed a series of systematic reviews to identify po-
tential connections between CD47 and these processes. The results indicated an ageing-
related increase in CD47 expression, which may contribute to the increased COVID-19
vulnerability in older patients [1]. Moreover, high CD47 levels are known to be in-
volved in vascular disease, vasoconstriction, and hypertension, which may predispose
SARS-CoV-2-infected individuals to various conditions associated with severe COVID-19
related, including pulmonary hypertension, lung fibrosis, myocardial injury, stroke, and
acute kidney injury [4,50–57].
High CD47 levels have also been reported as a consequence of hyperglycemia and
diabetes, which may contribute to the high risk of severe COVID-19 in diabetic patients [4].
Although there is no known direct impact of obesity on CD47 levels, obesity is associated
with an increased risk of diabetes and other ageing-related conditions such as hypertension,
which may result in elevated COVID-19 vulnerability [4].
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5. Conclusions
Severe COVID-19 disease is a consequence of hyperinflammation (“cytokine storm”)
in response to SARS-CoV-2 infection [1]. Hence, the optimal time window for antiviral
intervention is as early as possible to prevent disease progression to severe stages driven
by immunopathology [1]. As the vast majority of cases are mild or even asymptomatic [1],
an improved understanding of the processes underlying severe COVID-19 is required for
the early identification of patients at high risk.
Here, we investigated a potential role of CD47 expression in determining COVID-19
severity. SARS-CoV-2 infection resulted in an enhanced expression of CD47 in different cell
types. CD47 interferes with the host immune response by mechanisms including binding
to SIRPα on immune cells. Notably, SARS-CoV-2 also increased SIRPα levels on primary
human monocytes, indicating that SARS-CoV-2 can interfere with the immune response by
elevating both binding partners of the CD47/ SIRPα axis.
Moreover, CD47 levels are elevated in groups at high risk for COVID-19, such as
older individuals and individuals with hypertension and/or diabetes. Thus, high CD47
levels may predispose these groups to severe COVID-19. Additionally, CD47 is a potential
therapeutic target that can be addressed with antibodies and small molecules [22–24,72].
Notably, targeting SIRPα also represents a therapeutic option that may be more specific, as
SIRPα is restricted to monocytes and macrophages [81]. Further research will be needed to
define the roles of CD47 and/or SIRPalpha in COVID-19 in more detail. Thus, our findings
should also encourage other research groups to consider the potential relevance of these
molecules in their COVID-19 research.
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